Digostics
Digostics is a UK health tech company offering GTT@home, the world's first regulatory-approved home oral glucose tolerance test, primarily serving NHS maternity services for gestational diabetes screening while expanding into cystic fibrosis, type 1, and type 2 diabetes detection across the UK, UAE, and Singapore.
- Company typePrivate
- Founded2019
- HeadquartersDidcot, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Digostics does
Digostics Limited is a UK-based health technology company, founded in 2019 and headquartered at the Harwell Innovation Centre in Didcot, that has developed GTT@home, described as the world's first and only home-based oral glucose tolerance test (OGTT) for diabetes detection. The platform received CE marking under Directive 98/79/EC and UKCA market authorization in 2022, and is sold as a managed diagnostic service to NHS trusts and health boards primarily for gestational diabetes mellitus (GDM) screening, with additional care pathways for cystic fibrosis diabetes, type 1 diabetes, and prediabetes/type 2 diabetes. The flagship site, University Hospital Southampton NHS Foundation Trust, was the first organization globally to implement GTT@home and reported a 100% recommendation rate from mothers and maternity staff.
Digostics firmographics
Firmographics- Name
- Digostics
- Legal name
- Digostics Limited
- Website
- https://digostics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Digostics is a UK health tech company offering GTT@home, the world's first regulatory-approved home oral glucose tolerance test, primarily serving NHS maternity services for gestational diabetes screening while expanding into cystic fibrosis, type 1, and type 2 diabetes detection across the UK, UAE, and Singapore.
- Ownership category
- akta.pro rank
Digostics industry classification
Industry- Product category
- Home Diagnostic Services
- NAICS
- Home Health Care Services (621610)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB)
- akta.pro secondary industries
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where Digostics is headquartered
LocationHeadquarters
- HQ city
- Didcot
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Digostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- GTT@home Managed Service: Solution-as-a-service model where Digostics provides test kits containing the novel GTT@home test device, preformulated glucose drink, finger prickers, and multilingual instructions. The test kit is mailed to patients at the scheduled test time. Includes software platform for scheduling tests and viewing patient results. Revenue generated through NHS contracts and health board agreements.
- NHS Supply Chain Framework: GTT@home is available on the NHS Supply Chain Laboratory Diagnostics, Point of Care Testing and Pathology Managed Services Framework, enabling NHS entities across the UK to procure the service through established procurement channels.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Digostics product offering
Product offeringCore offering
Digostics develops and delivers GTT@home, the world's first and only regulatory-approved home oral glucose tolerance test (OGTT) for diabetes detection. The solution is sold as a managed service to healthcare providers (primarily NHS trusts and health boards), comprising a proprietary test device, pre-formulated glucose drink, finger prickers, multilingual instructions, a companion mobile application that transmits results via NFC, and a clinician-facing scheduling and review software platform built on HL7 FHIR standards. The platform enables gestational diabetes, cystic fibrosis-related diabetes, type 1 diabetes, and prediabetes/type 2 diabetes screening to be performed entirely at home.
Product overview
Digostics offers GTT@home, a comprehensive home-based oral glucose tolerance testing solution-as-a-service. The core product is the GTT@home test kit, which includes a proprietary test device, pre-formulated glucose drink, and finger prickers. This is complemented by a mobile application for patients to transmit results via smartphone NFC, and a software platform for healthcare providers to schedule tests and review results. The solution serves multiple diabetes detection applications including gestational diabetes, cystic fibrosis diabetes, type 1 diabetes, and prediabetes/type 2 diabetes, all using the same underlying home OGTT platform with application-specific care pathways. Multilingual support in Bengali and Farsi extends accessibility across patient demographics.
Differentiator
Problem solved
Functional benefit
Products and services
- GTT@home Home OGTT Service Managed home oral glucose tolerance testing service for diabetes detection, comprising a proprietary test device, pre-formulated glucose drink, finger prickers, multilingual instructions, a companion mobile app for NFC result transmission, and a clinician scheduling and review platform. CE-marked and UKCA-authorized. Sold to NHS trusts and health boards via the NHS Supply Chain framework and direct contracts.
- GTT@home for Gestational Diabetes Care pathway configuration of GTT@home for gestational diabetes mellitus (GDM) screening in expectant mothers assessed as at-risk by midwives, enabling at-home OGTT completion without in-clinic fasting visits.
- GTT@home for Cystic Fibrosis Diabetes Care pathway configuration of GTT@home for annual cystic fibrosis-related diabetes (CFD) screening in people with cystic fibrosis aged 10+, reducing cross-infection risks and treatment burden by avoiding clinic visits.
- GTT@home for Type 1 Diabetes Care pathway configuration of GTT@home enabling home-based OGTT for type 1 diabetes detection and monitoring in at-risk populations.
- GTT@home for Prediabetes & Type 2 Diabetes Care pathway configuration of GTT@home enabling home-based OGTT for early detection of prediabetes and type 2 diabetes, supporting earlier clinical intervention in at-risk populations.
Quantifiable outcome
- 97% test completion rate with 92% user satisfaction (4+ out of 5)
- +5 more outcomes
Companies that use Digostics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Digostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature5 records
Digostics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, flagship and minor.
- AgaMatrix EuropecoreIn April 2024, Digostics partnered with AgaMatrix Europe to exclusively distribute Digostics' home oral glucose tolerance testing service within the UK National Health Service. This partnership enables expanded distribution of GTT@home to NHS trusts and health boards across the UK.
- University Hospital Southampton NHS Foundation TrustflagshipPartnership to launch the world's first home OGTT testing service for gestational diabetes. UHS became the first organization globally to implement GTT@home, conducting a pilot in November 2022 before moving to higher volume implementation in 2023. The collaboration aims to improve GDM screening accessibility and quality.
- Contracts for Innovation CymruminorDigostics was invited to contribute to exploratory workshops across Wales focusing on improving healthcare access for rural, remote and disadvantaged communities. The workshops explored the role of emerging healthcare spaces including modular, pop-up or mobile facilities for service delivery.
- Clinical and Academic Partners (Innodia, Yale, Swansea, Southampton, JDRF, Oxford, Johnson & Johnson, King's College London)coreDigostics maintains partnerships with leading clinical advisors and academic institutions including Innodia, Yale University, Swansea University, University of Southampton, JDRF, Oxford University, Johnson & Johnson, and King's College London to drive innovation in diabetes testing and screening.
- NHS Supply ChaincoreGTT@home is available on the NHS Supply Chain Laboratory Diagnostics, Point of Care Testing and Pathology Managed Services Framework, making it easier for NHS entities across the United Kingdom to procure the service.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Digostics competitors and assessment
Company assessmentDirect peers
- Healthy.io: Healthy.io offers smartphone-based home diagnostic testing (e.g., urinalysis kits) sold to healthcare providers and payers on a managed-service basis. Highly comparable business model: home diagnostic test, mobile companion app, B2B health-system channel, and value proposition of converting clinic-based diagnostics into patient-administered at-home kits.
- LetsGetChecked: LetsGetChecked provides a broad portfolio of at-home self-collected diagnostic tests (hormones, sexual health, cancer screening) shipped directly to consumers and through enterprise health partners. Comparable as a home-based diagnostic testing platform with a kit-plus-app-plus-cloud-results architecture and B2B/B2B2C distribution.
- DarioHealth: DarioHealth combines a smartphone-connected blood glucose meter, app-based coaching, and chronic-condition management delivered to payers and employers. Comparable as a digital diabetes platform that moves glucose testing out of clinics onto a consumer device paired with a connected software platform.
- mySugr (Roche): mySugr offers a diabetes self-management app bundled with connected blood glucose meters, acquired by Roche. Comparable digital diabetes workflow with smartphone-centric data capture and chronic-condition tooling, addressing a similar population of self-monitoring diabetes patients.
Broad incumbents
- Roche Diabetes Care: Roche Diabetes Care is one of the largest global players in blood glucose monitoring systems, insulin delivery, and diabetes management software. Comparable as an established diabetes diagnostics incumbent with the channel reach, regulatory footprint, and R&D budget to compete with or acquire home OGTT capability.
- Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre franchise is the global consumer/professional continuous glucose monitoring leader. Comparable as a large-scale diabetes diagnostics incumbent with deep NHS and global payer relationships and a roadmap of adjacent glucose-detection products.
- Dexcom: Dexcom is the leading pure-play continuous glucose monitoring company, with sensors, apps, and cloud-based diabetes management platforms used by individuals and healthcare systems. Comparable as a connected-glucose-diagnostics platform player with established NHS and global distribution.
- Ascensia Diabetes Care: Ascensia Diabetes Care markets the Contour range of blood glucose meters and test strips globally, with strong pharmacy and health-system channels. Comparable as an established blood-glucose-monitoring device manufacturer whose portfolio could plausibly extend into home OGTT.
- LifeScan: LifeScan is a long-standing blood glucose monitoring company (OneTouch brand) with global retail and healthcare channels. Comparable as a legacy BGM incumbent whose installed meter base and distribution could host or compete against home OGTT capability.
Emerging players
- Nova Biomedical: Nova Biomedical manufactures hospital and point-of-care blood glucose analyzers and biosensor instruments used in clinical laboratories and ICUs. Comparable as a specialist POCT glucose-metabolism diagnostics vendor serving hospitals and reference labs — a credible fast-follower into the home OGTT category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Digostics social profiles
Digital presenceDigostics compliance and trust
Trust signalCompliance4 records
Digostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Digostics leadership team
Management profileNumber of profiles
Profiles4 records
Digostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Digostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Digostics
What does Digostics do?
Digostics develops and delivers GTT@home, the world's first and only regulatory-approved home oral glucose tolerance test (OGTT) for diabetes detection. The solution is sold as a managed service to healthcare providers (primarily NHS trusts and health boards), comprising a proprietary test device, pre-formulated glucose drink, finger prickers, multilingual instructions, a companion mobile application that transmits results via NFC, and a clinician-facing scheduling and review software platform built on HL7 FHIR standards. The platform enables gestational diabetes, cystic fibrosis-related diabetes, type 1 diabetes, and prediabetes/type 2 diabetes screening to be performed entirely at home.
Is Digostics a public or private company?
Digostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Digostics founded?
Digostics was founded in 2019. It employs 1 to 10 people.
Where is Digostics based?
Digostics is headquartered in Didcot, United Kingdom, in the Europe region.
How does Digostics make money?
Two revenue lines are on record. GTT@home Managed Service is the primary driver. The others are NHS Supply Chain Framework.
Who are Digostics's main competitors?
Direct peers on record are Healthy.io, LetsGetChecked, DarioHealth and mySugr (Roche). Broad incumbents are Roche Diabetes Care, Abbott Diabetes Care (FreeStyle Libre), Dexcom, Ascensia Diabetes Care and LifeScan. Nova Biomedical is listed as an emerging player.
Does Digostics have an API?
Yes. Digostics offers an API for clinical users to perform tasks such as scheduling tests and analysing data from within their preferred adjacent hospital systems. The API is part of the company's open architecture approach, built with HL7 FHIR standards to ensure system interoperability.
What industry is Digostics in?
Digostics's product category is Home Diagnostic Services. Its primary akta.pro industry code is HLAHAOAB, Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 621610 and its SIC code is 2835.